| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Leukemia | |||||
| Lymphoma | |||||
| 2 | More general conditions related to this trial | ||||
| Immune System Diseases | |||||
| Immunoproliferative Disorders | |||||
| Lymphatic Diseases | |||||
| Lymphoproliferative Disorders | |||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| 3 | Interventions listed in this trial | ||||
| amifostine trihydrate | |||||
| carboplatin | |||||
| filgrastim | |||||
| paclitaxel | |||||
| 4 | Additional drug interventions recognized in this trial | ||||
| Amifostine | |||||
| 5 | More general drug interventions related to this trial | ||||
| Antimitotic Agents | |||||
| Antineoplastic Agents | |||||
| Antineoplastic Agents, Phytogenic | |||||
| Mitosis Modulators | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Protective Agents | |||||
| Radiation-Protective Agents | |||||
| Therapeutic Uses | |||||
| Tubulin Modulators | |||||
| 6 | Sponsors listed in this trial | ||||
| Roswell Park Cancer Institute | |||||
| National Cancer Institute (NCI) | |||||
|
